Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy.

[1]  R. Herbst,et al.  COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Hodge,et al.  Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape , 2022, Nature Reviews Drug Discovery.

[3]  K. Politi,et al.  Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC , 2022, JCI insight.

[4]  Yong Wang,et al.  The cell-surface 5′-nucleotidase CD73 defines a functional T memory cell subset that declines with age , 2021, Cell reports.

[5]  J. Sosman,et al.  701 Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC) , 2021, Journal for ImmunoTherapy of Cancer.

[6]  T. Guo,et al.  Abstract 1871: A differentiated CD73 blocking antibody with a unique intra-dimer binding mechanism for cancer immunotherapy , 2021, Immunology.

[7]  C. Theuer,et al.  Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer. , 2021 .

[8]  Eva Bric-Furlong,et al.  A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms , 2020, The Journal of Biological Chemistry.

[9]  Bin Zhang,et al.  Targeting CD73 to augment cancer immunotherapy. , 2020, Current opinion in pharmacology.

[10]  Yonghui Wang,et al.  Adenosine A2A Receptor Antagonists for Cancer Immunotherapy. , 2020, Journal of medicinal chemistry.

[11]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[12]  Bo Peng,et al.  Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit , 2019, mAbs.

[13]  T. Gebhardt,et al.  Tissue-Resident Memory T Cells in Cancer Immunosurveillance. , 2019, Trends in immunology.

[14]  A. Hotson,et al.  Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers. , 2019, Journal of Clinical Oncology.

[15]  A. Roussel,et al.  Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. , 2019, Cell reports.

[16]  T. Burns,et al.  Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer? , 2019, Translational lung cancer research.

[17]  N. Rizvi,et al.  P3.04-23 Phase 1b/2 Study to Evaluate Novel Combinations With Oleclumab (MEDI9447) in Previously Treated Advanced EGFRm NSCLC , 2018, Journal of Thoracic Oncology.

[18]  A. Klippel,et al.  Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors , 2018, Clinical Trials.

[19]  J. Desai,et al.  Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc). , 2018 .

[20]  C. Sotiriou,et al.  Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. Madrigal,et al.  B cell regulation in cancer and anti-tumor immunity , 2017, Cellular &Molecular Immunology.

[22]  H. Sugimura,et al.  Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer , 2017, Oncotarget.

[23]  I. Palomo,et al.  Role of adenosine A2b receptor overexpression in tumor progression. , 2016, Life sciences.

[24]  R. Hollingsworth,et al.  Targeting CD73 in the tumor microenvironment with MEDI9447 , 2016, Oncoimmunology.

[25]  J. Bendell,et al.  A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors. , 2016 .

[26]  Herren Wu,et al.  Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action , 2016, mAbs.

[27]  G. Beatty,et al.  Immune Escape Mechanisms as a Guide for Cancer Immunotherapy , 2014, Clinical Cancer Research.

[28]  Benjamin,et al.  Site-Directed Mutagenesis in Epitope Mapping , 1996, Methods.